Close

Nymox Pharma (NYMX) Announces Phase 3 Long-Term Fexapotide Repeat Injection BPH Trial Results

Go back to Nymox Pharma (NYMX) Announces Phase 3 Long-Term Fexapotide Repeat Injection BPH Trial Results
Nymox Pharmaceutical Corp (NASDAQ: NYMX) Delayed: 0.20 --0 (-0%)
Previous Close $0.20    52 Week High $5.79 
Open $0.20    52 Week Low $1.62 
Day High $0.20    P/E N/A 
Day Low $0.20    EPS $-0.18 
Volume 629,050